



**CONFIDENTIAL TO REGULATORY AUTHORITIES**

**Biological Clinical Safety and Pharmacovigilance  
GlaxoSmithKline Research and Development  
Avenue Fleming, 20 1300 Wavre Belgium**

**Combined Diphtheria, Tetanus and Acellular Pertussis, Hepatitis B  
enhanced Inactivated Poliomyelitis and *Haemophilus influenzae* type B  
vaccine**



**Infanrix™ hexa**

**Summary Bridging Report**

**Date of the Report: 16 December 2011**

**International Birthdate: 23 October 2000 (European Union)**

**Data Lock Points : 23 October 2009 to 22 October 2011**

|   |                                 |
|---|---------------------------------|
| <b>Author</b>   |                                 |
| Vanessa Coremans,<br>Safety Scientist   |                                 |
| <br>Signature                                | <u>16 December 2011</u><br>Date |
| <b>Reviewer</b>   |                                 |
| Dr. Felix Arellano, MD<br>Vice President, Head Biological Clinical Safety and Pharmacovigilance,<br>GlaxoSmithKline Biologicals |                                 |
| <br>Signature                                | <u>16.12.2011</u><br>Date       |